Prognostic impact of 18F-FDG PET/CT in patients with multiple myeloma presenting with renal impairment

Seo Yeon Ahn; Hwa Kyung Park; Joon Ho Moon; Dong Won Baek; Hee Jeong Cho; Sang Kyun Sohn; Sae Ryung Kang; Jung Joon Min; Hee Seung Bom; Chae Moon Hong; Shin Young Jeong; Ga Young Song; Deok Hwan Yang; Jae Sook Ahn; Hyeoung Joon Kim; Sung Hoon Jung; Je Jung Lee

doi:10.1007/s12185-021-03079-w

Prognostic impact of ¹⁸F-FDG PET/CT in patients with multiple myeloma presenting with renal impairment

Seo Yeon Ahn, Hwa Kyung Park, Joon Ho Moon, Dong Won Baek, Hee Jeong Cho, Sang Kyun Sohn, Sae Ryung Kang, Jung Joon Min, Hee Seung Bom, Chae Moon Hong, Shin Young Jeong, Ga Young Song, Deok Hwan Yang, Jae Sook Ahn, Hyeoung Joon Kim, Sung Hoon Jung, Je Jung Lee

Department of Medicine

Research output: Contribution to journal › Article › peer-review

Abstract

Renal insufficiency (RI) is a frequent manifestation of multiple myeloma (MM) at time of diagnosis but there is no reliable prognostic factor for patients with MM presenting with RI. This study investigated the prognostic impact of ¹⁸F-fluorodeoxyglucose (¹⁸F-FDG) positron emission tomography/computed tomography (PET/CT) in patients with MM with RI at diagnosis. The records of 209 patients with MM between June 2011 and November 2018 were retrospectively analyzed. PET/CT positivity was defined as the presence of more than three focal lesions or the presence of extramedullary disease. Of 209 patients, 90 (43.1%) had RI and showed similar survival outcomes to patients who had normal renal function. In total, 113 patients (54.0%) were PET/CT-positive, and 46.6% of patients with RI were PET/CT-positive at baseline. In patients with RI, those who were PET/CT-positive showed significantly inferior survival outcomes to those who were PET/CT-negative [progression-free survival (PFS), 12.7 vs. 34.0 months, P < 0.001; overall survival (OS), 42.2 months vs. not reached, P = 0.001]. On multivariate analysis, PET/CT positivity was significantly associated with PFS and OS in patients with RI. In conclusion, PET/CT is a reliable imaging technique for predicting survival outcomes in patients with MM with RI.

Original language	English
Pages (from-to)	668-674
Number of pages	7
Journal	International Journal of Hematology
Volume	113
Issue number	5
DOIs	https://doi.org/10.1007/s12185-021-03079-w
State	Published - May 2021

Keywords

Multiple myeloma
Positron emission tomography
Prognosis
Renal insufficiency

Access to Document

10.1007/s12185-021-03079-w

Cite this

Ahn, S. Y., Park, H. K., Moon, J. H., Baek, D. W., Cho, H. J., Sohn, S. K., Kang, S. R., Min, J. J., Bom, H. S., Hong, C. M., Jeong, S. Y., Song, G. Y., Yang, D. H., Ahn, J. S., Kim, H. J., Jung, S. H., & Lee, J. J. (2021). Prognostic impact of ¹⁸F-FDG PET/CT in patients with multiple myeloma presenting with renal impairment. International Journal of Hematology, 113(5), 668-674. https://doi.org/10.1007/s12185-021-03079-w

@article{ebbb846047ce4f828d1ed6c6be851e80,

title = "Prognostic impact of 18F-FDG PET/CT in patients with multiple myeloma presenting with renal impairment",

abstract = "Renal insufficiency (RI) is a frequent manifestation of multiple myeloma (MM) at time of diagnosis but there is no reliable prognostic factor for patients with MM presenting with RI. This study investigated the prognostic impact of 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography/computed tomography (PET/CT) in patients with MM with RI at diagnosis. The records of 209 patients with MM between June 2011 and November 2018 were retrospectively analyzed. PET/CT positivity was defined as the presence of more than three focal lesions or the presence of extramedullary disease. Of 209 patients, 90 (43.1%) had RI and showed similar survival outcomes to patients who had normal renal function. In total, 113 patients (54.0%) were PET/CT-positive, and 46.6% of patients with RI were PET/CT-positive at baseline. In patients with RI, those who were PET/CT-positive showed significantly inferior survival outcomes to those who were PET/CT-negative [progression-free survival (PFS), 12.7 vs. 34.0 months, P < 0.001; overall survival (OS), 42.2 months vs. not reached, P = 0.001]. On multivariate analysis, PET/CT positivity was significantly associated with PFS and OS in patients with RI. In conclusion, PET/CT is a reliable imaging technique for predicting survival outcomes in patients with MM with RI.",

keywords = "Multiple myeloma, Positron emission tomography, Prognosis, Renal insufficiency",

author = "Ahn, {Seo Yeon} and Park, {Hwa Kyung} and Moon, {Joon Ho} and Baek, {Dong Won} and Cho, {Hee Jeong} and Sohn, {Sang Kyun} and Kang, {Sae Ryung} and Min, {Jung Joon} and Bom, {Hee Seung} and Hong, {Chae Moon} and Jeong, {Shin Young} and Song, {Ga Young} and Yang, {Deok Hwan} and Ahn, {Jae Sook} and Kim, {Hyeoung Joon} and Jung, {Sung Hoon} and Lee, {Je Jung}",

note = "Publisher Copyright: {\textcopyright} 2021, Japanese Society of Hematology.",

year = "2021",

month = may,

doi = "10.1007/s12185-021-03079-w",

language = "English",

volume = "113",

pages = "668--674",

journal = "International Journal of Hematology",

issn = "0925-5710",

publisher = "Springer",

number = "5",

}

Ahn, SY, Park, HK, Moon, JH, Baek, DW, Cho, HJ, Sohn, SK, Kang, SR, Min, JJ, Bom, HS, Hong, CM, Jeong, SY, Song, GY, Yang, DH, Ahn, JS, Kim, HJ, Jung, SH & Lee, JJ 2021, 'Prognostic impact of ¹⁸F-FDG PET/CT in patients with multiple myeloma presenting with renal impairment', International Journal of Hematology, vol. 113, no. 5, pp. 668-674. https://doi.org/10.1007/s12185-021-03079-w

TY - JOUR

T1 - Prognostic impact of 18F-FDG PET/CT in patients with multiple myeloma presenting with renal impairment

AU - Ahn, Seo Yeon

AU - Park, Hwa Kyung

AU - Moon, Joon Ho

AU - Baek, Dong Won

AU - Cho, Hee Jeong

AU - Sohn, Sang Kyun

AU - Kang, Sae Ryung

AU - Min, Jung Joon

AU - Bom, Hee Seung

AU - Hong, Chae Moon

AU - Jeong, Shin Young

AU - Song, Ga Young

AU - Yang, Deok Hwan

AU - Ahn, Jae Sook

AU - Kim, Hyeoung Joon

AU - Jung, Sung Hoon

AU - Lee, Je Jung

PY - 2021/5

Y1 - 2021/5

N2 - Renal insufficiency (RI) is a frequent manifestation of multiple myeloma (MM) at time of diagnosis but there is no reliable prognostic factor for patients with MM presenting with RI. This study investigated the prognostic impact of 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography/computed tomography (PET/CT) in patients with MM with RI at diagnosis. The records of 209 patients with MM between June 2011 and November 2018 were retrospectively analyzed. PET/CT positivity was defined as the presence of more than three focal lesions or the presence of extramedullary disease. Of 209 patients, 90 (43.1%) had RI and showed similar survival outcomes to patients who had normal renal function. In total, 113 patients (54.0%) were PET/CT-positive, and 46.6% of patients with RI were PET/CT-positive at baseline. In patients with RI, those who were PET/CT-positive showed significantly inferior survival outcomes to those who were PET/CT-negative [progression-free survival (PFS), 12.7 vs. 34.0 months, P < 0.001; overall survival (OS), 42.2 months vs. not reached, P = 0.001]. On multivariate analysis, PET/CT positivity was significantly associated with PFS and OS in patients with RI. In conclusion, PET/CT is a reliable imaging technique for predicting survival outcomes in patients with MM with RI.

AB - Renal insufficiency (RI) is a frequent manifestation of multiple myeloma (MM) at time of diagnosis but there is no reliable prognostic factor for patients with MM presenting with RI. This study investigated the prognostic impact of 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography/computed tomography (PET/CT) in patients with MM with RI at diagnosis. The records of 209 patients with MM between June 2011 and November 2018 were retrospectively analyzed. PET/CT positivity was defined as the presence of more than three focal lesions or the presence of extramedullary disease. Of 209 patients, 90 (43.1%) had RI and showed similar survival outcomes to patients who had normal renal function. In total, 113 patients (54.0%) were PET/CT-positive, and 46.6% of patients with RI were PET/CT-positive at baseline. In patients with RI, those who were PET/CT-positive showed significantly inferior survival outcomes to those who were PET/CT-negative [progression-free survival (PFS), 12.7 vs. 34.0 months, P < 0.001; overall survival (OS), 42.2 months vs. not reached, P = 0.001]. On multivariate analysis, PET/CT positivity was significantly associated with PFS and OS in patients with RI. In conclusion, PET/CT is a reliable imaging technique for predicting survival outcomes in patients with MM with RI.

KW - Multiple myeloma

KW - Positron emission tomography

KW - Prognosis

KW - Renal insufficiency

UR - http://www.scopus.com/inward/record.url?scp=85100181518&partnerID=8YFLogxK

U2 - 10.1007/s12185-021-03079-w

DO - 10.1007/s12185-021-03079-w

M3 - Article

C2 - 33475961

AN - SCOPUS:85100181518

SN - 0925-5710

VL - 113

SP - 668

EP - 674

JO - International Journal of Hematology

JF - International Journal of Hematology

IS - 5

ER -

Prognostic impact of ¹⁸F-FDG PET/CT in patients with multiple myeloma presenting with renal impairment

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this